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Copyright © 2018 D. Magalhães et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thyroid carcinoma is the most common endocrine neoplasia. Differentiated thyroid carcinomas (DTCs) represent the majority
of cases, which usually follow an indolent clinical course with low mortality rates. The authors describe two cases of well DTC
without classic histological poor prognosis features, presenting as extensive and unresectable osteolytic bone metastases. DTCs are
considered harmless tumours, due to their benign and silent behaviour. The authors want to underline the importance of clinical
awareness during follow-up in cases of DTC, which can be aggressive in presentation and behaviour. Timely identification and
diagnosis of these tumours are essential for prompt treatment initiation and improvement of overall survival.
1. Introduction
The most common endocrine neoplasia is the thyroid car-
cinoma, with a rapidly increasing incidence worldwide [1–
3]. The majority (>90%) of thyroid cancers are differentiated
thyroid carcinomas (DTC)—papillary or follicular—which
follow, in most cases, an indolent clinical course with low
mortality rates [4, 5].
When distant metastases occur, the bone is the second
most frequently affected site [6]. The incidence of bone
metastases is about 1 to 7% in papillary carcinoma and 7
to 20% in follicular carcinoma. When present, the lesions
are mostly osteolytic in nature [2, 7]. Bone metastases
can result in clinically significant morbidity, coursing with
important pain, pathological fractures, and neurological
dysfunction [2, 6]. However, clinically silent presentation
of bone metastases can also occur [2]. The presence of
bone metastases is associated with a worse prognosis, lower
survival rates, and significant deterioration of quality of life
[2].
The authors report two cases of DTC without significant
microscopic adverse features presenting as lytic bone metas-
tases.
2. Case 1
A 62-year-old male presented with refractory sacral coc-
cygeal pain. The patient had past medical history of type 2
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Figure 1: Fragments of bone tissue involved by epithelial neoplasia of follicular architecture, with foci of nondifferentiated (insular) carcinoma
[Case 1].
(a) (b)
Figure 2: Malignant cells revealing intense and diffuse immunoexpression of thyroglobulin (cytoplasmic) (a) and TTF-1 (nuclear) (b) [Case
1].
diabetes mellitus (treated with linagliptin/metformin), non-
treated high blood pressure, right-sided hemiparesis follow-
ing meningitis in childhood, nephrolithiasis, and smoking
history. The pelvic computed tomography (CT) revealed a
9x7.5x9 cm bulky mass in the sacrum with locally increased
soft tissue density, causing extensive lytic lesions of the sacred
vertebrae and extending to the left iliac bone, suggestive
of chordoma. The patient underwent total sacrectomy with
partial excision and reconstruction of the left iliac bone. The
anatomopathological examination revealed sacrococcygeal
involvement by a thyroid carcinoma, as verified by immuno-
histochemical staining for thyroglobulin and TTF-1, pre-
dominantly papillary (follicular variant), however with foci
of nondifferentiated (insular) carcinoma (Figures 1 and 2).
Thyroid ultrasonography showed a solid nodule of 20mm in
the right lobe and two solid hypoechogenic nodules of 11 and
9mm in the left lobe, the smallest with coarse calcifications.
No lymphadenopathies were found. 18F-fluorodeoxyglucose
positron-emission tomography (18F-FDG-PET) revealed a
hypermetabolic focus in the left lobe of the thyroid, consistent
with the suspected malignant neoplasia, and uptake of the
radiopharmaceutical drug in the fifth lumbar vertebra and
pelvic bones, consistent with secondary involvement (Fig-
ure 3). Consequently, the patient underwent total thyroidec-
tomy. Histological examination revealed only follicular and
oxyphilic variants of multifocal papillary carcinoma (at least
six foci) and none of insular carcinoma, with dimensions
ranging from 2 to 15mm, without signs of hematogenic,
lymphatic, or perineural permeation, as well as no signs
of invasion of the capsule or extrathyroidal extension, with
resection margins uninvolved by tumour (pT1b[m]NxM1R0)
(Figure 4). Radioactive iodine therapy (RAI) was then
performed. Posttherapy scintigraphy showed hyperfixation
in the remnants of the sacrum and lower lumbar spine,
bilateral iliac bone, and anterior cervical region (Figure 5).
TSH-stimulated thyroglobulin was 24490 ng/mL. Follow-up
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Figure 3: 18F-FDG-PET showing uptake of the radiopharmaceutical drug in thyroid left lobe, L5 vertebrae, and pelvic bones [Case 1].
Figure 4: Fragments of thyroid involved by papillary thyroid
carcinoma of follicular and oxyphilic variants [Case 1].
magnetic resonance imaging (MRI) revealed persistence and
progression of the pelvic lesion. At this time the patient was
unable to walk, had a chronic indwelling bladder catheter,
suffered from fecal incontinence, and presented with uncon-
trolled refractory chronic pain.
3. Case 2
A 64-year-oldmale presented with pain in the left iliac region
for 6months. His past medical history was significant for gas-
tric peptic ulcer disease (submitted to partial gastrectomy and
Figure 5: Posttherapy scintigraphy showing hyperfixation in the
remnants of the sacrum and lower lumbar spine, bilateral iliac bone,
and anterior cervical region [Case 1].
chronically treated with lansoprazole), nephrolithiasis, and
hyperuricemia. At admission a poorly defined mass on the
left posterior iliac crest was palpable. The patient underwent
a pelvic CT, which revealed a 9 cm lytic lesion of left iliac
bone with soft tissue involvement (Figure 6). A biopsy was
performed and the histological examination and immuno-
histochemical staining for thyroglobulin and TTF-1 showed
iliac involvement of a well-differentiated thyroid carcinoma
(Figures 7 and 8).Thyroid ultrasonography disclosed a poorly
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Figure 6: Pelvic CT revealing a 9 cm lytic lesion of left iliac bone
[Case 2].
defined 8mm nodule in the left inferior lobe, heterogeneous
and partially calcified, and a 4mm hypoechoic nodule in
the right lobe, without associated lymphadenopathies. The
patient was submitted to total thyroidectomy and anato-
mopathological examination revealed a 1.1 cmpapillary carci-
noma, of follicular variant, with capsular invasion and limited
extrathyroidal extension (ETE). Consequently, RAI therapy
was performed. Postablative 131 iodine scintigraphy and 18F-
FDG-PET (Figure 9) did not reveal further lesions. TSH-
stimulated thyroglobulin was 185051 ng/mL. The patient is
currently waiting for a hemipelvectomy.
4. Discussion
The authors present two rare cases of well DTC without
significant histological poor prognosis features presenting as
osteolytic bonemetastases. DTCs, in particular those that are
small and organ confined as in the above-mentioned cases,
are often characterized by a slowly progressive course with a
5-year survival rate of 98.2% [8]. Of the several histological
subtypes of papillary carcinoma, the follicular variants are
probably the most common. At the time of diagnosis, distant
metastases are seen in 2 to 10% of patients: two-thirds
are pulmonary and one-fourth is represented by skeletal
metastases [9]. Metastization at the time of the diagnosis of
well DTC is an unusual combination, with poor prognosis.
Moreover, according to the most recent data from Cancer
Care Ontario, distant metastases occur in less than 1% of all
thyroid cancer patients [10].
However, the bone is the third most common site of
metastatic cancer of unknown origin, particularly of the
spine, followed by the pelvis and long bones [11]. In such
cases, bone biopsy is mandatory, since histological findings
often provide important diagnostic clues, as well as important
information regarding the prognosis and treatment of these
patients [11]. This is particularly true in bone metastases
from DTC [11]. In the first described case the radiological
features were highly suggestive of a chordoma, dictating the
choice of immediate resection, and pathological examination
established the diagnosis of a thyroid carcinoma. In the
second case, bone biopsy was diagnostic.
The described cases are unusual due to the aggressive
presentation in the absence of previous poor prognosis anato-
mopathological features of the primitive tumours. In the first
case report, beyond multifocality no other unfavourable fea-
tures were present, predicting a low risk DTC [4]. However,
the histological examination of the excised bone metastasis
revealed insular carcinoma foci, suggesting primary tumour
dedifferentiation during the process of distant metastization.
In fact, DTCs can undergo dedifferentiation through a pro-
cess of multiple genetic and epigenetic alterations, evolving
into poor differentiated or even undifferentiated/anaplastic
carcinomas [12]. The histological findings of bone metastasis
in the first case, according to theTurin criteria, are compatible
with a poorly differentiated thyroid carcinoma (PDTC),
defined as a follicular-cell neoplasm with insular, solid, or
trabecular growth [12, 13]. This type of tumour constitutes
an entity that, in terms of morphology and behaviour, is
considered of intermediate risk between papillary and follic-
ular well DTCs and anaplastic carcinomas [12]. Significant
regional differences in the incidence of this type of tumour
are found, suggesting that their etiology is multifactorial and
results from the interaction of genetic, environmental, and
diet related factors [12, 14]. Furthermore, there are reports
of tumours, which, even in the absence of any identifiable
dedifferentiation marker, behave aggressively. In the sec-
ond case report, capsular and microscopically immediate
perithyroidal soft tissue invasion was present, estimating an
intermediate risk DTC following 2015 ATA guidelines [4].
Nevertheless, the definition of limited/microscopic ETE is
subjective, as the thyroid lacks a well-defined capsule and
is often intermingled with adipose tissue or even peripheral
skeletal muscle. Even so, recent studies have shown that gross
ETE constitutes a strong predictor for recurrence anddisease-
related death, and that limited ETE alone does not have a
significant impact on survival. Consequently, some authors
questioned whether microscopic ETE should be sufficient to
increase the risk of persistent/recurrent disease from low to
intermediate or to upstage a DTC as T3 [1]. Furthermore,
none of the cases presented with vascular or lymphoid
invasion, which could predict a more aggressive conduct and
the presence of extensive bone metastases.
Nevertheless, the factors predicting a worse outcome in
DTCs also include demographic features.There is established
evidence that male sex and increasing age are important risk
modifiers [12]. The latest study from The Cancer Genome
Atlas (TCGA) Research Network has shown that mutation
density correlates with age and therefore age should always
be considered as a continuous variable in risk stratification,
rather than a static threshold from which patients are clas-
sified as having low or high risk [15]. The patients above-
mentioned were both men and over 60 years old.
Although DTC has often an indolent course and usually
poses minimal risk to human health, without apparent
symptoms or adverse impact from their disease burden for
many years, the casesmentioned abovemean to underline the
notion that patients can have an aggressive presentation and
behaviour despite relatively “benign” histological features.
In order to complement the histological study, it would be
interesting to design a molecular study of the described
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Figure 7: Fragments of bone tissue involved by epithelial neoplasia of follicular architecture [Case 2].
(a) (b)
Figure 8: Malignant cells revealing intense and diffuse immunoexpression of thyroglobulin (cytoplasmic) (a) and TTF-1 (nuclear) (b) [Case
2].
Figure 9: 18F-FDG-PET revealing the pelvic lesion found on CT,
without no other metabolically active lesions [Case 2].
tumours in an attempt to identify mutations that could serve
as predictors for a more aggressive behaviour. DTCs are
heterogeneous with different molecular signatures and vari-
able presentation. A variety of molecular markers is involved
in the processes of tumorigenesis, tumour progression, and
development, including focal mutations, rearrangements,
epigenetic changes of growth factors and their receptors,
angiogenesis mediators, cellular regulators, and adhesion
molecules. Because overall survival is improved by complete
resection of the primary tumour and its metastases, early
diagnosis and treatment are crucial.
5. Conclusions
DTC are commonly tumours with a benign clinical course.
However, patients presenting with seemingly innocent fea-
tures may have aggressive tumours with bone metastization
upon diagnosis. Prompt treatment initiation is crucial for
patient survival. The authors want to underline the necessity
of high clinical awareness and close follow-up to decrease
morbidity andmortality in these patients. Further studies are
needed to disclose clinical and histological patterns of poor
prognosis.
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